MCID: BCK003
MIFTS: 38

Background Diabetic Retinopathy

Categories: Cardiovascular diseases, Eye diseases

Aliases & Classifications for Background Diabetic Retinopathy

MalaCards integrated aliases for Background Diabetic Retinopathy:

Name: Background Diabetic Retinopathy 12 15
Non Proliferative Diabetic Retinopathy 12
Non-Proliferative Diabetic Retinopathy 12
Nonproliferative Diabetic Retinopathy 74

Classifications:



External Ids:

Disease Ontology 12 DOID:13208
ICD9CM 36 362.01 362.03
NCIt 51 C35668
SNOMED-CT 69 31411005
UMLS 74 C0004606

Summaries for Background Diabetic Retinopathy

MalaCards based summary : Background Diabetic Retinopathy, also known as non proliferative diabetic retinopathy, is related to microvascular complications of diabetes 1 and severe nonproliferative diabetic retinopathy. An important gene associated with Background Diabetic Retinopathy is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and PI3K-Akt signaling pathway. The drugs Ranibizumab and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and endothelial.

Related Diseases for Background Diabetic Retinopathy

Diseases related to Background Diabetic Retinopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 47)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 32.5 AKR1B1 ANGPT2 INS VEGFA
2 severe nonproliferative diabetic retinopathy 32.3 ALB INS VEGFA
3 diabetes mellitus 29.8 AKR1B1 ALB INS VEGFA
4 microvascular complications of diabetes 5 29.7 AKR1B1 ALB ANGPT2 INS VEGFA
5 microvascular complications of diabetes 2 10.8
6 hypoglycemic coma 10.3 INS VEGFA
7 rubeosis iridis 10.2 INS VEGFA
8 noma 10.2 ALB INS
9 pyogenic granuloma 10.2 ANGPT2 VEGFA
10 acroosteolysis 10.2 ALB VEGFA
11 burns 10.2 ALB INS
12 angiodysplasia 10.2 ANGPT2 VEGFA
13 lipodermatosclerosis 10.2 ANGPT2 VEGFA
14 drug allergy 10.2 ALB INS
15 hypertensive nephropathy 10.2 ALB VEGFA
16 gastric lymphoma 10.2 ALB VEGFA
17 microvascular complications of diabetes 3 10.2 ALB INS
18 fetal erythroblastosis 10.1 ALB INS
19 fascioliasis 10.1 ALB INS
20 autonomic nervous system disease 10.1 ALB INS
21 macular holes 10.1 ANGPT2 VEGFA
22 hydrops, lactic acidosis, and sideroblastic anemia 10.1 ALB VEGFA
23 cataract 10.1
24 macular retinal edema 10.1
25 diabetic cataract 10.1 AKR1B1 VEGFA
26 diabetic autonomic neuropathy 10.1 AKR1B1 INS
27 prediabetes syndrome 10.1 ALB INS
28 epileptic encephalopathy, childhood-onset 10.1 ANGPT2 VEGFA
29 diabetic polyneuropathy 10.1 AKR1B1 VEGFA
30 vein disease 10.1 ALB VEGFA
31 vascular disease 10.1 ALB INS VEGFA
32 arteries, anomalies of 10.0 ALB INS VEGFA
33 hepatopulmonary syndrome 10.0 ALB VEGFA
34 urinary system disease 10.0 ALB INS VEGFA
35 nervous system disease 10.0 ALB INS VEGFA
36 gastrointestinal system disease 10.0 ALB INS VEGFA
37 diabetic neuropathy 10.0 AKR1B1 INS VEGFA
38 lens disease 10.0 AKR1B1 VEGFA
39 intermittent claudication 9.9 ALB ANGPT2 VEGFA
40 limb ischemia 9.9 ANGPT2 VEGFA
41 autonomic neuropathy 9.9 AKR1B1 ALB INS
42 peripheral nervous system disease 9.8 AKR1B1 ALB INS
43 hyperglycemia 9.8 AKR1B1 ALB INS
44 diabetes mellitus, insulin-dependent 9.8 AKR1B1 ALB INS
45 placental insufficiency 9.8 ANGPT2 VEGFA
46 large intestine cancer 9.8 ALB INS VEGFA
47 retinal vascular disease 9.7 AKR1B1 ALB INS VEGFA

Graphical network of the top 20 diseases related to Background Diabetic Retinopathy:



Diseases related to Background Diabetic Retinopathy

Symptoms & Phenotypes for Background Diabetic Retinopathy

Drugs & Therapeutics for Background Diabetic Retinopathy

Drugs for Background Diabetic Retinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 3,Phase 1,Phase 2 347396-82-1 459903
2
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
3
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
4
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
5
leucovorin Approved Phase 4 58-05-9 6006 143
6
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
7
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
8
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-30-3 6037
9
Cobalamin Experimental Phase 4 13408-78-1 6857388
10 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
11 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
12 Antineoplastic Agents, Immunological Phase 4,Phase 2,Phase 3,Phase 1
13 Vitamin B 12 Phase 4
14 Hematinics Phase 4
15 Nutrients Phase 4,Phase 2,Not Applicable
16 Vitamin B Complex Phase 4,Not Applicable
17 Vitamins Phase 4,Phase 3,Phase 2,Not Applicable
18 Trace Elements Phase 4,Phase 2,Not Applicable
19 Micronutrients Phase 4,Phase 2,Not Applicable
20 Vitamin B9 Phase 4,Not Applicable
21 Folate Phase 4,Not Applicable
22 Vitamin B 6 Phase 4
23 Vitamin B12 Phase 4
24 Hypoglycemic Agents Phase 4,Phase 3
25 insulin Phase 4,Phase 3,Not Applicable
26 Insulin, Globin Zinc Phase 4,Phase 3,Not Applicable
27
Pyridoxal Experimental, Nutraceutical Phase 4 66-72-8 1050
28
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
29
Nepafenac Approved, Investigational Phase 3 78281-72-8 151075
30
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
31
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
32
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
33
Fenofibrate Approved Phase 3 49562-28-9 3339
34
Simvastatin Approved Phase 3 79902-63-9 54454
35
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
36
Tocopherol Approved, Investigational Phase 3,Phase 2,Not Applicable 1406-66-2 14986
37
Zinc Approved, Investigational Phase 3,Phase 2 7440-66-6 32051
38
Copper Approved, Investigational Phase 3,Phase 2 7440-50-8 27099
39
Zinc oxide Approved Phase 3 1314-13-2
40
Magnesium oxide Approved Phase 3 1309-48-4 14792
41
Octreotide Approved, Investigational Phase 3 83150-76-9 6400441 383414
42
Vitamin C Approved, Nutraceutical Phase 3,Phase 2,Not Applicable 50-81-7 5785 54670067
43
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Not Applicable 59-02-9 14985
44
Lutein Approved, Investigational, Nutraceutical Phase 3,Phase 2,Not Applicable 127-40-2 6433159
45
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
46
Ruboxistaurin Investigational Phase 3 202260-21-7, 169939-94-0 153999
47 Tocotrienol Investigational Phase 3,Phase 2,Not Applicable 6829-55-6
48 Chinese Salvia Phase 3
49 Antirheumatic Agents Phase 3
50 Gastrointestinal Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
2 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
3 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
4 Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment Unknown status NCT00563043 Phase 4
5 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
6 Avastin for Post-Photocoagulation Macular Edema Completed NCT00801866 Phase 4 Bevacizumab
7 Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME. Completed NCT02581995 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
8 CPAP Effect on the Progression of Diabetic Retinopathy in Patients With Sleep Apnea Recruiting NCT02874313 Phase 4 Pharmacological treatment
9 Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy Unknown status NCT02388984 Phase 3 Compound danshen dripping pills;Placebo
10 A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects Unknown status NCT00908778 Phase 3 Vitreosolve;Vitreosolve
11 Nepafenac Once Daily for Macular Edema - Study 2 Completed NCT01872611 Phase 3 Nepafenac Ophthalmic Suspension, 0.3%;Prednisolone acetate
12 Nepafenac Once Daily for Macular Edema - Study 1 Completed NCT01853072 Phase 3 Nepafenac Ophthalmic Suspension, 0.3%;Prednisolone acetate
13 Intravitreal Bevacizumab for Diabetic Retinopathy Completed NCT00600262 Phase 2, Phase 3 intravitreal bevacizumab
14 Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study) Completed NCT00542178 Phase 3 Hypoglycemic Agents;Standard glycemia control;Intensive BP treatment;Standard BP control;Fenofibrate;Simvastatin;Placebo
15 Reduction in the Occurrence of Center-Involved Diabetic Macular Edema Completed NCT00090519 Phase 3 ruboxistaurin;placebo
16 Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema Completed NCT00444600 Phase 3 Triamcinolone Acetonide + laser;Ranibizumab + laser;Sham injection + laser;Ranibizumab + deferred laser
17 Treatment for CI-DME in Eyes With Very Good VA Study Completed NCT01909791 Phase 3 Prompt aflibercept;Deferred aflibercept
18 Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement Completed NCT01783886 Phase 3
19 Combined Antioxidant Therapy on Oxidative Stress, Mitochondrial Dysfunction Markers in Diabetic Retinopathy Recruiting NCT03702374 Phase 3 Combined antioxidant therapy
20 PROMINENT-Eye Ancillary Study (Protocol AD) Recruiting NCT03345901 Phase 3 Pemafibrate;Placebo
21 Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) Active, not recruiting NCT02718326 Phase 3 Intravitreal aflibercept injection [IAI];Sham
22 Anti-VEGF Treatment for Prevention of PDR/DME Active, not recruiting NCT02634333 Phase 3 Prompt aflibercept;Deferred aflibercept
23 Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy Terminated NCT00248131 Phase 3 Octreotide acetate in microspheres
24 Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy Terminated NCT00248157 Phase 3 Octreotide acetate in microspheres
25 A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects Terminated NCT00664183 Phase 2, Phase 3 Vitreosolve
26 The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy Unknown status NCT03006081 Phase 2 Intravitreal Aflibercept injection
27 Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab Unknown status NCT01845844 Phase 1, Phase 2 Ranibizumab 0.3mg/0.05cc
28 Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy Completed NCT02062034 Phase 2 Ubiquinone;Combined antioxidant therapy;Placebo
29 A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy Completed NCT02435862 Phase 2 1.0mg Luminate®;2.0mg Luminate®;3.0mg Luminate®
30 Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy Completed NCT00917553 Phase 2 doxycycline monohydrate;Placebo
31 Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment Completed NCT00198471 Phase 2 Vitrase
32 Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema Completed NCT01571232 Phase 2 dexamethasone intravitreal implant;intravitreal bevacizumab
33 Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE) Completed NCT01552408 Phase 1, Phase 2 0.3 mg ranibizumab
34 A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated. Recruiting NCT03238963 Phase 2 BI 1467335;Placebo
35 The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) Active, not recruiting NCT03197870 Phase 2 AKB-9778;Placebo
36 A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR Active, not recruiting NCT02681809 Phase 2 ocriplasmin 0.0625mg;ocriplasmin 0.125mg;Sham injection
37 A Study of Keluo Xin Capsule Compare to Placebo in Terms of Efficacy and Safety in Patients With Diabetic Retinopathy Not yet recruiting NCT03258242 Phase 2 Keluo Xin capsule;Placebo oral capsule
38 Panretinal Photo-stimulation in Proliferative Diabetic Retinopathy Unknown status NCT02309502 Not Applicable
39 Blood-retinal Barrier Imaging and Neuropsychiatric Sequela in Type 2 Diabetes Mellitus Unknown status NCT01107132
40 Early Laser Treatment for Diabetic Eye Disease in China : A Pilot Randomized Trial Unknown status NCT02956759 Not Applicable
41 Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography Unknown status NCT01790945
42 Study on Tear Proteins in Diabetic Retinopathy of Type 2 Diabetics Unknown status NCT00698698
43 Phenotypes of Nonproliferative Diabetic Retinopathy in DM 2 Patients Identified by OCT, CFP, RLA and mfERG (DIAMARKER) Completed NCT01440660
44 Validation of a Predictive Model to Estimate the Risk of Conversion to Clinically Significant Macular Edema and/or Vision Loss in Mild Nonproliferative Diabetic Retinopathy in Diabetes Type 2 Completed NCT00763802
45 Identifying Progression of Retinal Disease in Eyes With NPDR in Diabetes Type 2 Using Non-invasive Procedures Completed NCT01145599
46 Biomarkers of Diabetic Retinopathy Progression Completed NCT01607190
47 Computer Detection of Diabetic Retinopathy Compared to Clinical Examination Completed NCT01625598
48 Diabetes Visual Function Supplement Study Completed NCT01646047 Not Applicable
49 Comparison of Retinal Oxygenation and Retinal Vessel Diameters in Healthy Subjects and Patients With Diabetic Retinopathy or Retinal Vein Occlusion Between DVA and Oxymap Completed NCT02521116 Not Applicable
50 Observational Study of DME Following Scatter Laser Photocoagulation Completed NCT00687154 Not Applicable

Search NIH Clinical Center for Background Diabetic Retinopathy

Genetic Tests for Background Diabetic Retinopathy

Anatomical Context for Background Diabetic Retinopathy

MalaCards organs/tissues related to Background Diabetic Retinopathy:

42
Eye, Liver, Endothelial, Testes

Publications for Background Diabetic Retinopathy

Articles related to Background Diabetic Retinopathy:

(show all 38)
# Title Authors Year
1
Factors associated with non-proliferative diabetic retinopathy in patients with type 1 and type 2 diabetes: the Japan Diabetes Complication and its Prevention prospective study (JDCP study 4). ( 30800559 )
2019
2
Prevalence of diabetic retinopathy, proliferative diabetic retinopathy and non-proliferative diabetic retinopathy in Asian T2DM patients: a systematic review and Meta-analysis. ( 30809489 )
2019
3
COMPARISON OF 3 MM × 3 MM VERSUS 6 MM × 6 MM OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY SCAN SIZES IN THE EVALUATION OF NON-PROLIFERATIVE DIABETIC RETINOPATHY. ( 29190249 )
2019
4
Role of combined phacoemulsification and intravitreal injection of bevacizumab in prevention of postoperative macular edema in non-proliferative diabetic retinopathy. ( 30197955 )
2018
5
Plasma metabolic profile reveals PGF2α protecting against non-proliferative diabetic retinopathy in patients with type 2 diabetes. ( 29408756 )
2018
6
The Correlation between Changes in Biochemical Parameters and Central Macular Thickness in Patients with Non-Proliferative Diabetic Retinopathy. ( 29644239 )
2018
7
Successful Midterm Management With an Herbal Decoction, Modified-Goshajinkigan (mGJG) for Non-Proliferative Diabetic Retinopathy: A Case Study. ( 29793732 )
2018
8
Nomogram for prediction of non-proliferative diabetic retinopathy in juvenile-onset type 1 diabetes: a cohort study in an Asian population. ( 30111889 )
2018
9
The unmet need for better risk stratification of non-proliferative diabetic retinopathy. ( 30474144 )
2018
10
Effect of topical nepafenac in prevention of macular edema after cataract surgery in patients with non-proliferative diabetic retinopathy. ( 28367202 )
2017
11
Non-proliferative diabetic retinopathy symptoms detection and classification using neural network. ( 28786703 )
2017
12
Automatic non-proliferative diabetic retinopathy screening system based on color fundus image. ( 29073912 )
2017
13
Fundus autofluorescence lifetimes are increased in non-proliferative diabetic retinopathy. ( 27519815 )
2017
14
Aqueous humour concentrations of TGF-β, PLGF and FGF-1 and total retinal blood flow in patients with early non-proliferative diabetic retinopathy. ( 27678201 )
2017
15
Pupillary responses in non-proliferative diabetic retinopathy. ( 28332564 )
2017
16
Effects of photocoagulation on ocular blood flow in patients with severe non-proliferative diabetic retinopathy. ( 28355247 )
2017
17
Aqueous humor endothelin-1 and total retinal blood flow in patients with non-proliferative diabetic retinopathy. ( 28548649 )
2017
18
Aqueous humour concentrations of TGF-β, PLGF and FGF-1 and total retinal blood flow in patients with early non-proliferative diabetic retinopathy. ( 28631371 )
2017
19
The effect of cilostazol on electrophysiologic changes in non-proliferative diabetic retinopathy patients. ( 27378278 )
2016
20
Association of macular pigment optical density with early stage of non-proliferative diabetic retinopathy in Chinese patients with type 2 diabetes mellitus. ( 27803860 )
2016
21
Effect of focal laser photocoagulation in eyes with mild to moderate non-proliferative diabetic retinopathy. ( 27803861 )
2016
22
The antioxidant effect of ubiquinone and combined therapy on mitochondrial function in blood cells in non-proliferative diabetic retinopathy: A randomized, double-blind, phase IIa, placebo-controlled study. ( 26207797 )
2016
23
The effect of ubiquinone and combined antioxidant therapy on oxidative stress markers in non-proliferative diabetic retinopathy: A phase IIa, randomized, double-blind, and placebo-controlled study. ( 26321469 )
2016
24
Characterisation of human non-proliferative diabetic retinopathy using the fractal analysis. ( 26309878 )
2015
25
Non-Proliferative Diabetic Retinopathy: is It Cost-Effective to Treat Early? ( 27202121 )
2014
26
The influence of background diabetic retinopathy in the second eye on rates of progression of diabetic retinopathy between 2005 and 2010. ( 23551550 )
2013
27
From minimal background diabetic retinopathy to profuse sight threatening vitreoretinal haemorrhage: management issues in a case of pregestational diabetes and pregnancy. ( 12873299 )
2003
28
Massive subretinal bleed in a patient with background diabetic retinopathy and on treatment with warfarin. ( 12855977 )
2003
29
Background diabetic retinopathy in Harare, Zimbabwe. ( 10448253 )
1999
30
Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. ( 9519746 )
1998
31
Bovine factor VIII derivative in the treatment of non-proliferative diabetic retinopathy. ( 7630622 )
1995
32
Contrast sensitivity changes in background diabetic retinopathy. ( 2013027 )
1991
33
Does increased platelet aggregation have a prognostic value in the deterioration of background diabetic retinopathy? The Damad Study Group. ( 2270529 )
1990
34
Treatment of background diabetic retinopathy. ( 3508804 )
1987
35
Pattern electroretinograms become abnormal when background diabetic retinopathy deteriorates to a preproliferative stage: possible use as a screening test. ( 3964635 )
1986
36
Blood pressure and the progression of mild background diabetic retinopathy. ( 4077241 )
1985
37
Effect of pure O2-breathing on retinal blood flow in normals and in patients with background diabetic retinopathy. ( 6690224 )
1984
38
Vitreous fluorophotometry and hemoglobin AIc in non-proliferative diabetic retinopathy. ( 6933817 )
1980

Variations for Background Diabetic Retinopathy

Expression for Background Diabetic Retinopathy

Search GEO for disease gene expression data for Background Diabetic Retinopathy.

Pathways for Background Diabetic Retinopathy

Pathways related to Background Diabetic Retinopathy according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.88 ALB ANGPT2 GNB2 GNB4 VEGFA
2
Show member pathways
12.19 ANGPT2 GNB2 GNB4 INS VEGFA
3
Show member pathways
11.99 GNB2 GNB4 INS
4 11.96 GNB2 GNB4 KCNH3
5
Show member pathways
11.78 GNB2 GNB4 INS
6 11.72 GNB2 GNB4 VEGFA
7
Show member pathways
11.66 ANGPT2 GNB2 GNB4 INS VEGFA
8 11.56 ALB INS VEGFA
9 11.33 ANGPT2 INS VEGFA
10 11.22 INS VEGFA
11 11.21 GNB2 GNB4
12 11.15 ALB INS
13
Show member pathways
11.12 INS VEGFA
14 11.05 ANGPT2 VEGFA

GO Terms for Background Diabetic Retinopathy

Cellular components related to Background Diabetic Retinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 AKR1B1 ALB ANGPT2 GNB2 INS VEGFA
2 myelin sheath GO:0043209 8.8 ALB GNB2 GNB4

Biological processes related to Background Diabetic Retinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.33 ALB INS ITIH2
2 maternal process involved in female pregnancy GO:0060135 8.96 AKR1B1 ANGPT2
3 positive regulation of protein autophosphorylation GO:0031954 8.62 INS VEGFA

Sources for Background Diabetic Retinopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....